年轻人群体基因组筛查家族性高胆固醇血症的成本效益分析
本研究通过决策分析马尔可夫模型,比较澳大利亚现行机会性胆固醇筛查联合基因级联检测与对18-40岁成人进行群体基因组筛查检出杂合子家族性高胆固醇血症(FH)的策略。
要点
- 社会角度群体筛查可节省成本,且适应其他国家后仍保持节省。
核心结论
- 基于模型,对全部年轻人提供FH群体基因组筛查在检测成本可行时具有成本效益。
研究设计与样本
- 决策分析马尔可夫模型,比较澳大利亚现行FH诊疗与18-40岁成人LDLR/APOB/PCSK9基因群体基因组筛查。
- 模型覆盖终生冠心病发病率/死亡率,从医疗保健和社会角度分析,成本与QALY年贴现5%。
- 采用经验证的成本适应方法将结果适应于八个高收入国家。
主要发现
- 从社会角度,群体基因组筛查可节省成本,且适应其他国家后仍节省成本。
关键数值与推荐
- 社会角度群体基因组筛查可节省成本。
临床怎么用
- 在检测成本可行时,可考虑对年轻人进行FH群体基因组筛查以预防冠心病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The aim of this study was to assess the impact and cost-effectiveness of offering population genomic screening to all young adults in Australia to detect heterozygous familial hypercholesterolaemia (FH). METHODS AND RESULTS: We designed a decision analytic Markov model to compare the current standard of care for heterozygous FH diagnosis in Australia (opportunistic cholesterol screening and genetic cascade testing) with the alternate strategy of population genomic screening of adults aged 18-40 years to detect pathogenic variants in the LDLR/APOB/PCSK9 genes. We used a validated cost-adaptation method to adapt findings to eight high-income countries. The model captured coronary heart disease (CHD) morbidity/mortality over a lifetime horizon, from healthcare and societal perspectives. Risk of CHD, treatment effects, prevalence, and healthcare costs were estimated from published studies. Outcomes included quality-adjusted life years (QALYs), costs and incremental cost-effectiveness ratio (ICER), discounted 5% annually. Sensitivity analyses were undertaken to explore the impact of key input parameters on the robustness of the model. Over the lifetime of the population (4 167 768 men; 4 129 961 women), the model estimated a gain of 33 488years of life lived and 51 790 QALYs due to CHD prevention. Population genomic screening for FH would be cost-effective from a healthcare perspective if the per-test cost was ≤AU$250, yielding an ICER of <AU$28 000 per QALY gained. From a societal perspective, population genomic screening would be cost-saving. ICERs from societal perspective remained cost-saving after adaptation to other countries. CONCLUSION: Based on our model, offering population genomic screening to all young adults for FH could be cost-effective, at testing costs that are feasible.
引用
- Marquina C, Lacaze P, Tiller J, et al. Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysis. Eur Heart J. 2022. PMID: 34788414. doi:10.1093/eurheartj/ehab770
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。